2076975 2077203
최종편집 2024-03-29 06:02 (금)
SpinrazaㆍK-CABㆍCabometyxㆍSaxenda, 2019 Rising Stars
상태바
SpinrazaㆍK-CABㆍCabometyxㆍSaxenda, 2019 Rising Stars
  • Hanki Lee
  • 승인 2020.03.07 06:52
  • 댓글 0
이 기사를 공유합니다

Top 4 growth rates among blockbusters
54 drugs became blockbusters
19 drugs left out of the blockbuster list

 

▲ Last year, 54 new drugs joined the list of blockbusters.
▲ Last year, 54 new drugs joined the list of blockbusters.

<KOREA> According to IQVIA, a total of 387 medicines achieved more than 10 billion won in annual sales last year, up 35 from 2018.

Among them, 54 drugs with sales of less than 10 billion won in 2018, newly joined the blockbuster list, while 19 other drugs left out of the lineup.

Of the 387 blockbuster drugs that sold more than 10 billion won last year, 30 drugs recorded more than 50% growth rate.

 

In particular, Spinraza(Biogen) sales were the most outstanding. Spinraza, which recorded sales of 10 billion won in the second quarter of last year, achieved 20.4 billion won in the third quarter followed by 15.9 billion won in the fourth quarter, totalling 46.4 billion won in annual sales in the first year of its release.

K-CAB(CJ Healthcare), which included in the IQVOA report for the first time in late 2018, also rocked the drug market, posting 31 billion won in sales last year.

Cabometyx(Ipsen), which had sales of only 1.6 billion won in 2018, also joined the blockbuster list, growing more than 700% to 13.2 billion won.

Saxenda(Novo Nordisk), which came out on top in the obesity treatment market, grew 465% from 7.5 billion won to 42.6 billion won in sales. Meanwhile, Mavyret, which became a blockbuster in the first year of its release in 2018, sales increased further to 57.3 billion won.

Cosentyx Sensoready(Novartis), Tecentriq(Roche), Lybliss(Huons Medicare) also became blockbusters with a growth rate of more than 200%, and Prolia(Amgen)’s sales rose sharply from 14.3 billion won to 47.3 billion won thanks to the effects of expanded reimbursement.

In addition, Herzuma(Celltrion), Ryzodeg Flex Touch(Novo Nordisk), Vemlidy(Gilead), Hameron A(Samchundang Pharm), Entresto(Novartis) were listed as blockbusters with a growth rate of over 100%.

Harvoni(Gilead), which sales declined for some time, rebounded on the back of expanded reimbursement and returned as a blockbuster. Alecensa(Roche), which became a blockbuster in 2018, further expanded its sales to 20 billion won.

Other newly joined blockbusters included Benfobell(Chong Kun Dang), Amosartan Plus(Hanmi Pharm), Profa(Dai Han Pharm), Naseron(Boryung Pharmaceutical), GC Fluquad Balant(GC Pharma), Xeljanz(Pfizer) with over 50% growth rate in sales.

Among the existing blockbusters, sales of Gardasil 9(MSD), Perjeta(Roche), Keytruda(MSD), Ibrance(Pfizer), Kyprolis(Amgen), Xigduo(MSD), Stelara(Janssen), Lixiana(Daiichi Sankyo) increased more than 50%.

On the other hand, sales of Sovaldi(Gilead), Zepatier(MSD), Tamiflu(Roche), Hanmi Flu(Hanmi Pharm) plunged more than 50%, left out from the blockbuster list.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.